¹⁸Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer

Keyphrases

• Pancreatic Cancer 100%
• 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) 100%
• Patient Management 100%
• Computed Tomography 38%
• Resection 23%
• Pancreatic Adenocarcinoma 23%
• Positron Emission Tomography 19%
• Neoadjuvant Chemoradiotherapy (nCRT) 19%
• Primary Tumor 14%
• Hepatic Metastasis 14%
• Pancreatic Carcinoma 14%
• Clinical Management 9%
• PET Imaging 4%
• Tumor Cells 4%
• High Incidence 4%
• High Specificity 4%
• Patient Assessment 4%
• 18F-fluorodeoxyglucose (18F-FDG) 4%
• Clinical Impact 4%
• Diagnostic Accuracy 4%
• Adenocarcinoma 4%
• Distant Metastasis 4%
• Glucose Metabolism 4%
• Tumor Metastasis 4%
• Tumor Response 4%
• High Sensitivity 4%
• Metastatic Disease 4%
• Benign Lesion 4%
• Recurrent Disease 4%
• Preoperative Diagnosis 4%
• Tumor Progression 4%
• Tumor Regression 4%
• Stable Disease 4%
• Local Recurrence 4%
• Anatomic Imaging 4%
• Advanced Imaging 4%
• Tomography Image 4%
• Postoperative Changes 4%
• Primary Hepatic 4%
• Uptake Ratio 4%
• Preoperative Studies 4%
• Metastatic Pancreatic Adenocarcinoma 4%
• New Regions 4%
• Pancreatic Mass 4%
• Non-therapeutic 4%
• Response to Neoadjuvant Therapy 4%
• Emission-computed 4%
• Celiotomy 4%
• Tumor Resectability 4%

Medicine and Dentistry

• Positron Emission Tomography 100%
• Pancreas Cancer 100%
• Pancreas Adenocarcinoma 30%
• Chemoradiotherapy 20%
• Primary Tumor 15%
• Liver Metastasis 15%
• Pancreas Carcinoma 15%
• Metastatic Carcinoma 10%
• Sensitivity and Specificity 10%
• Recurrent Disease 10%
• Clinical Management 10%
• Polyethylene Terephthalate 10%
• Neoplasm 5%
• Tumor Cell 5%
• Patient Care 5%
• Diagnostic Accuracy 5%
• Distant Metastasis 5%
• Adenocarcinoma 5%
• Glucose Metabolism 5%
• Imaging Technique 5%
• Neoadjuvant Therapy 5%
• Tumor Progression 5%
• Anatomic Imaging 5%
• Tumor Regression 5%
• Grading (Tumors) 5%
• Diseases 5%